Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.87 USD

105.87
498,510

-0.58 (-0.55%)

Updated Nov 11, 2024 12:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab

by Zacks Equity Research

FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Kinjel Shah headshot

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

by Kinjel Shah

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

by Zacks Equity Research

Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

Novartis (NVS) Announces Data on Radioligand Therapy at ASCO

by Zacks Equity Research

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study

by Zacks Equity Research

AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.

Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer

by Zacks Equity Research

FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies

by Kinjel Shah

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

by Zacks Equity Research

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU

by Zacks Equity Research

The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.

J&J's (JNJ) Multiple Sclerosis Drug Ponvory Gets EU Approval

by Zacks Equity Research

J&J's (JNJ) oral multiple sclerosis drug, Ponvory, receives approval in Europe after demonstrating superior efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.

Kinjel Shah headshot

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

by Kinjel Shah

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints

Incyte (INCY) Announces Positive Results From Vitiligo Study

by Zacks Equity Research

Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.

Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

by Zacks Equity Research

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi

by Zacks Equity Research

Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.

Kinjel Shah headshot

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

by Kinjel Shah

Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

Kinjel Shah headshot

Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs

by Kinjel Shah

Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.

Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.

Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More

by Zacks Equity Research

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes

by Zacks Equity Research

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?

by Zacks Equity Research

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.

Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra

by Zacks Equity Research

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.

Celcuity (CELC) Soars on Agreement With Pfizer & Study Data

by Zacks Equity Research

Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.

Novartis (NVS) Teams Up With Artios for Radioligand Therapies

by Zacks Equity Research

Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.

AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis

by Zacks Equity Research

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.